Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of high-frequency low-dose rituximab and acalabrutinib in chronic lymphocytic leukemia.

HemaSphere·2026
Same author

Inhibition of Complement Will Substantially Reduce the Anemia of Malaria.

Journal of immunology research·2025
Same author

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells.

Blood·2025
Same author

T cells reinforce NK cell-mediated ADCC.

Blood·2024
Same author

Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms.

Blood·2024
Same author

Measurement of Trogocytosis: Quantitative Analyses Validated with Rigorous Controls.

Current protocols·2023

Related Experiment Video

Updated: Jun 14, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Antigenic modulation and rituximab resistance.

Ronald P Taylor1, Margaret A Lindorfer

  • 1Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22908, USA. rpt@virginia.edu

Seminars in Hematology
|March 31, 2010
PubMed
Summary
This summary is machine-generated.

Rituximab therapy for B-cell lymphoma and rheumatoid arthritis can fail. High rituximab doses may exhaust immune cells, leading to B-cell resistance via CD20 shaving by macrophages.

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Related Experiment Videos

Last Updated: Jun 14, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Area of Science:

  • Immunology
  • Oncology
  • Rheumatology

Background:

  • Rituximab targets CD20 on B cells for lymphoma and rheumatoid arthritis.
  • High-dose rituximab may saturate immune effector mechanisms.
  • This saturation can lead to alternative B-cell processing pathways.

Purpose of the Study:

  • Investigate the consequences of rituximab-induced effector mechanism saturation.
  • Elucidate the mechanism of B-cell resistance to rituximab therapy.
  • Understand the role of CD20 shaving in therapeutic failure.

Main Methods:

  • Analysis of B-cell opsonization and effector cell interactions.
  • Investigation of FcgammaR-mediated pathways in rituximab therapy.
  • Study of CD20 and rituximab dynamics on B cells.

Main Results:

  • High rituximab burdens can exhaust complement and NK cell functions.
  • Opsonized B cells are processed via FcgammaR on monocytes/macrophages.
  • This pathway involves "shaving" of CD20 and rituximab from B cells.

Conclusions:

  • CD20 shaving by macrophages is a key mechanism of rituximab resistance.
  • Understanding this pathway may lead to improved therapeutic strategies.
  • Further research is needed to overcome rituximab resistance in B-cell malignancies and autoimmune diseases.